Related Experiment Videos
Alopecia areata in childhood
1Department of Dermatology and Pediatrics, Medical University of South Carolina, Charleston 29425-2215, USA.
Seminars in Dermatology
|March 1, 1995
Summary
Alopecia areata affects about 1% of people, often starting in childhood. While treatments are limited, immunotherapy shows promise, and psychological support is crucial for affected children.
Area of Science:
- Dermatology
- Immunology
- Systemic Autoimmune Diseases
Background:
- Alopecia areata (AA) affects approximately 1% of the population by age 50, with peak incidence in children and young adults.
- This condition can lead to complete body hair loss, including eyelashes and eyebrows, and is considered a systemic disease.
- AA is frequently associated with other conditions such as atopic dermatitis, autoimmune disorders, vitiligo, and endocrine diseases.
Purpose of the Study:
- To summarize the current understanding of alopecia areata.
- To highlight the challenges in treatment and emerging therapeutic options.
- To emphasize the importance of addressing the psychological impact of alopecia areata, particularly in pediatric patients.
Main Methods:
- Review of existing literature on alopecia areata.
- Analysis of associated conditions and systemic involvement.
- Evaluation of current and experimental treatment strategies.
Main Results:
- Alopecia areata has a significant prevalence, particularly in younger populations.
- The disease's pathogenesis remains largely unknown.
- Current therapies are not consistently effective, necessitating further research and novel approaches.
Conclusions:
- Alopecia areata is a complex systemic condition with significant physical and psychological implications.
- Immunotherapy, such as with diphenylcyclopropenone, is an area of ongoing research.
- Preventative measures and psychological support are essential for children experiencing alopecia areata.